NCT04467801View on ClinicalTrials.gov

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2025

Conditions
NSCLC Stage IVNSCLC Stage IIIB
Interventions
DRUG

Ipatasertib

Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.

Trial Locations (5)

64064

ACTIVE_NOT_RECRUITING

The University of Kansas Cancer Center, Lee's Summit Clinic, Lee's Summit

64154

ACTIVE_NOT_RECRUITING

The University of Kansas Cancer Center, North Clinic, Kansas City

66205

RECRUITING

The University of Kansas Cancer Center (KUCC), Fairway

RECRUITING

The University of Kansas Cancer Center, Westwood Campus, Kansas City

66210

ACTIVE_NOT_RECRUITING

The University of Kansas Cancer Center, Overland Park Clinic, Overland Park

All Listed Sponsors
collaborator

University of Iowa

OTHER

collaborator

University of Kentucky

OTHER

lead

Jun Zhang, MD, PhD

OTHER